Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 261

1.

Tumor necrosis factor-α accelerates the resolution of established pulmonary fibrosis in mice by targeting profibrotic lung macrophages.

Redente EF, Keith RC, Janssen W, Henson PM, Ortiz LA, Downey GP, Bratton DL, Riches DW.

Am J Respir Cell Mol Biol. 2014 Apr;50(4):825-37. doi: 10.1165/rcmb.2013-0386OC.

2.

Effect of an immunotoxin to folate receptor beta on bleomycin-induced experimental pulmonary fibrosis.

Nagai T, Tanaka M, Hasui K, Shirahama H, Kitajima S, Yonezawa S, Xu B, Matsuyama T.

Clin Exp Immunol. 2010 Aug;161(2):348-56. doi: 10.1111/j.1365-2249.2010.04182.x. Epub 2010 Jun 9.

3.

TNF-α-induced NF-κB activation promotes myofibroblast differentiation of LR-MSCs and exacerbates bleomycin-induced pulmonary fibrosis.

Hou J, Ma T, Cao H, Chen Y, Wang C, Chen X, Xiang Z, Han X.

J Cell Physiol. 2018 Mar;233(3):2409-2419. doi: 10.1002/jcp.26112. Epub 2017 Aug 25.

PMID:
28731277
4.

Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-β signaling.

Oruqaj G, Karnati S, Vijayan V, Kotarkonda LK, Boateng E, Zhang W, Ruppert C, Günther A, Shi W, Baumgart-Vogt E.

Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):E2048-57. doi: 10.1073/pnas.1415111112. Epub 2015 Apr 6.

5.

Surfactant protein-D regulates effector cell function and fibrotic lung remodeling in response to bleomycin injury.

Aono Y, Ledford JG, Mukherjee S, Ogawa H, Nishioka Y, Sone S, Beers MF, Noble PW, Wright JR.

Am J Respir Crit Care Med. 2012 Mar 1;185(5):525-36. doi: 10.1164/rccm.201103-0561OC. Epub 2011 Dec 28.

6.

Syndecan-2 exerts antifibrotic effects by promoting caveolin-1-mediated transforming growth factor-β receptor I internalization and inhibiting transforming growth factor-β1 signaling.

Shi Y, Gochuico BR, Yu G, Tang X, Osorio JC, Fernandez IE, Risquez CF, Patel AS, Shi Y, Wathelet MG, Goodwin AJ, Haspel JA, Ryter SW, Billings EM, Kaminski N, Morse D, Rosas IO.

Am J Respir Crit Care Med. 2013 Oct 1;188(7):831-41. doi: 10.1164/rccm.201303-0434OC.

7.
8.

Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice.

Ortiz LA, Lasky J, Hamilton RF Jr, Holian A, Hoyle GW, Banks W, Peschon JJ, Brody AR, Lungarella G, Friedman M.

Exp Lung Res. 1998 Nov-Dec;24(6):721-43.

PMID:
9839161
9.

Overexpression of tumor necrosis factor-alpha diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-beta.

Fujita M, Shannon JM, Morikawa O, Gauldie J, Hara N, Mason RJ.

Am J Respir Cell Mol Biol. 2003 Dec;29(6):669-76. Epub 2003 Jun 19.

PMID:
12816730
10.

Alveolar macrophage apoptosis and TNF-alpha, but not p53, expression correlate with murine response to bleomycin.

Ortiz LA, Moroz K, Liu JY, Hoyle GW, Hammond T, Hamilton RF, Holian A, Banks W, Brody AR, Friedman M.

Am J Physiol. 1998 Dec;275(6 Pt 1):L1208-18.

PMID:
9843859
11.

Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis.

Xie Y, Jiang H, Zhang Q, Mehrotra S, Abel PW, Toews ML, Wolff DW, Rennard S, Panettieri RA Jr, Casale TB, Tu Y.

Respir Res. 2016 Aug 22;17(1):103. doi: 10.1186/s12931-016-0418-4.

12.

IRAK-M promotes alternative macrophage activation and fibroproliferation in bleomycin-induced lung injury.

Ballinger MN, Newstead MW, Zeng X, Bhan U, Mo XM, Kunkel SL, Moore BB, Flavell R, Christman JW, Standiford TJ.

J Immunol. 2015 Feb 15;194(4):1894-904. doi: 10.4049/jimmunol.1402377. Epub 2015 Jan 16.

13.

Amelioration of bleomycin-induced pulmonary fibrosis in a mouse model by a combination therapy of bosentan and imatinib.

Chilakapati SR, Serasanambati M, Vissavajjhala P, Kanala JR, Chilakapati DR.

Exp Lung Res. 2015 May;41(4):173-88. doi: 10.3109/01902148.2014.939312. Epub 2015 Apr 6.

PMID:
25844688
14.

Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis.

Craig VJ, Zhang L, Hagood JS, Owen CA.

Am J Respir Cell Mol Biol. 2015 Nov;53(5):585-600. doi: 10.1165/rcmb.2015-0020TR. Review.

15.

Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis.

Kim TH, Lee YH, Kim KH, Lee SH, Cha JY, Shin EK, Jung S, Jang AS, Park SW, Uh ST, Kim YH, Park JS, Sin HG, Youm W, Koh ES, Cho SY, Paik YK, Rhim TY, Park CS.

Am J Respir Crit Care Med. 2010 Sep 1;182(5):633-42. doi: 10.1164/rccm.200905-0659OC. Epub 2010 May 12.

PMID:
20463180
16.

Complex regulation of pulmonary inflammation and fibrosis by CCL18.

Pochetuhen K, Luzina IG, Lockatell V, Choi J, Todd NW, Atamas SP.

Am J Pathol. 2007 Aug;171(2):428-37. Epub 2007 Jun 14.

17.
18.

Paired immunoglobulin-like receptor-B inhibits pulmonary fibrosis by suppressing profibrogenic properties of alveolar macrophages.

Karo-Atar D, Moshkovits I, Eickelberg O, Königshoff M, Munitz A.

Am J Respir Cell Mol Biol. 2013 Apr;48(4):456-64. doi: 10.1165/rcmb.2012-0329OC.

PMID:
23258232
19.

Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice.

Udalov S, Dumitrascu R, Pullamsetti SS, Al-tamari HM, Weissmann N, Ghofrani HA, Guenther A, Voswinckel R, Seeger W, Grimminger F, Schermuly RT.

BMC Pulm Med. 2010 May 5;10:26. doi: 10.1186/1471-2466-10-26.

20.

Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis.

Ghebremariam YT, Cooke JP, Gerhart W, Griego C, Brower JB, Doyle-Eisele M, Moeller BC, Zhou Q, Ho L, de Andrade J, Raghu G, Peterson L, Rivera A, Rosen GD.

J Transl Med. 2015 Aug 1;13:249. doi: 10.1186/s12967-015-0614-x.

Supplemental Content

Support Center